✦ LIBER ✦

Piritrexim in Advanced, Refractory Carcinoma of the Urothelium (E3896): A Phase II Trial of the Eastern Cooperative Oncology Group

✍ Scribed by Bruce J. Roth; Judith Manola; Robert Dreicer; David Graham; George Wilding

Book ID: 110398236
Publisher: Springer US
Year: 2002
Tongue: English
Weight: 64 KB
Volume: 20
Category: Article
ISSN: 0167-6997
DOI: 10.1023/a:1020675017737

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Taxol in advanced, hormone-refractory ca

Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the eastern cooperative oncology group

✍ Bruce J. Roth; Patrick J. Loehrer; Beow Yong Yeap; George Wilding; Basil Kasimis 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 440 KB 👁 2 views

Phase II trial of gemcitabine and doceta

Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium : A trial of the Eastern Cooperative Oncology Group

✍ Robert Dreicer; Judith Manola; Daniel J. Schneider; John F. Schwerkoske; Christo 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB 👁 2 views

## Abstract ## BACKGROUND Gemcitabine and docetaxel are active agents in advanced urothelial carcinoma. A Phase II trial of this combination was performed to determine the activity and toxicity of these agents in a multiinstitutional setting in patients previously treated with one prior chemothera

Phase 2 trial of epothilone B analog BMS

Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800) : A trial of the eastern cooperative oncology group

✍ Robert Dreicer; Shuli Li; Judith Manola; Naomi B. Haas; Bruce J. Roth; George Wi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 1 views

## Abstract ## BACKGROUND. Paclitaxel and docetaxel are active agents in advanced urothelial cancer. BMS‐247550 (ixabepilone) has activity in preclinical models in paclitaxel resistant models. A phase 2 trial of this epothilone was performed to determine the activity and toxicity of this agent in

An eastern cooperative oncology group ph

An eastern cooperative oncology group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma

✍ Robert S. Witte; Paul Elson; Janardan Khandakar; Donald L. Trump 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 359 KB 👁 2 views

## Background. Trimetrexate is an antifol that differs from methotrexate in ways that may be clinically important. Because methotrexate has activity in advanced bladder cancer, this trial was initiated.

Phase II study of paclitaxel plus carbop

Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896) : A trial of the Eastern Cooperative Oncology Group

✍ David J. Vaughn; Judith Manola; Robert Dreicer; William See; Ralph Levitt; Georg 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 2 views

## Background: Chemotherapy options for the patients with advanced urothelial carcinoma and renal dysfunction are limited. the authors performed a phase ii trial of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction. ## Methods: Forty-two patie

Phase II trial of gemcitabine in patient

Phase II trial of gemcitabine in patients with advanced sarcomas (E1797) : A trial of the Eastern Cooperative Oncology Group

✍ Scott Okuno; Louise M. Ryan; John H. Edmonson; Dennis A. Priebat; Ronald H. Blum 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 2 views

## Abstract ## BACKGROUND The current study was conducted to evaluate the antitumor activity and toxicity of gemcitabine in patients with advanced sarcoma. ## METHODS Twenty‐five patients with advanced sarcomas, who previously were untreated for metastatic disease, were treated on an Eastern Coo